Recent Headlines
Within Biotechnology
Pharmacodynamic PAR ELISA Assay
Trevigen introduces a highly sensitive, quantitative and validated assay to measure the effectiveness of PARP inhibitors in cell and tissue lysates for anticancer drug screening. - October 10, 2008 - Trevigen, Inc.
Utilising Cost Reduction Opportunities: Conference on "Optimising Stability Testing" in London
International experts discussed how to realise more efficient stability tests for medicinal products last Thursday and Friday (18 and 19 September) in London. At the two-day "Optimising Stability Testing" conference Dr Sven Oliver Kruse, managing director of Diapharm Analytics GmbH (www.diapharm.com), was one of those explaining how the burden of ongoing stability tests can be reduced with improved study design. - October 01, 2008 - Diapharm
Baxa Corporation Announces USP 797 Course to be Hosted at the STAR Center
Baxa announces it has signed a hosting agreement with the United States Pharmacopeia (USP) for compliance training through the Baxa STAR Center (Skills Training, Academics and Resources) continuing education facility in Englewood, Colorado. Baxa and USP plan to hold 16 sessions of their Compliance Tools for USP 797 course in 2009. - September 30, 2008 - Baxa Corporation
Protein Kinase CK2: New Perspectives of an Old Kinase
Novel, efficient at low micromolar concentrations, and selective CK2 inhibitors [1-7] has been recently designed by OTAVA Ltd., a leading Ukrainian company. To discover new inhibitors, company’s researchers spanned computer-based molecular modeling with chemical synthesis of compounds which were further tested in vitro to investigate their ability to bind to and affect the activity of CK2. The binding modes of inhibitors that target the ATP-binding site of CK2 were also studied. - September 26, 2008 - OTAVA Chemicals Ltd.
Baxa Corp Now Ranks in Top 35 of Largest Private Companies in Denver Area
Englewood-based Baxa Corporation has been named among the top 35 largest private companies in the area by both the Denver Business Journal (DBJ) and ColoradoBiz Magazine. In each publication, Baxa was in the Top 35 for 2008 – moving up five places to #32 in the DBJ (up from #37 in 2007) and #33 in ColoradoBiz (up from #38 in 2007). - September 25, 2008 - Baxa Corporation
NeoCardium Ltd – A New Service Facilitates Regenerative Cardiology Drug Development
A new super specialty regenerative cardiology service launched to support successful clinical development of novel treatments for heart conditions that can be benefited by promoting growth of new tissue to replace, supplement or revascularize the non-functional or under-functioning myocardium. - September 25, 2008 - MRI Limited
TBTA - Click Chemistry Ligand for Cu (I)
Copper (I) species are powerful catalysts for the formation of 1,2,3-triazoles from azides and alkynes. The general thermodynamic instability of Cu(I) however, results in easy oxidation to Cu(II) and/or disproportionation to Cu(0) and Cu(II).1 TBTA, Tris-[(1-benzyl-1H-1,2,3-triazol-4-yl)... - September 24, 2008 - AnaSpec, EGT Group
Genomic Nanosystems Announces Exclusive Licensing Agreement to Sequenom for the Right to Use Digital PCR in Prenatal Testing and Mass Spectrometry
Genomic Nanosystems, LLC, today announced that it has granted an exclusive license to Sequenom, Inc. (Nasdaq: SQNM) for the right to use Digital PCR in noninvasive prenatal research and diagnostics on a technology, platform and sample independent basis, and has granted the exclusive right to use... - September 22, 2008 - Genomic Nanosystems
Colorado BioScience Association, Colorado Springs Economic Development Corp and CEA Technologies, Inc., Promote the State’s Bioscience Industry AdvaMed MedTech Conference
The Colorado BioScience Association (CBSA), Colorado Springs Economic Development Corporation and CEA Technologies, Inc. are joining forces to promote the State’s burgeoning bioscience industry at the AdvaMed 2008 MedTech Conference in Washington, D.C., September 21-24. Participation in this premier event for medical device manufacturers will showcase Colorado’s CEA Technologies, Inc., a leader in the contract design and manufacture of disposable and reusable electromechanical devices. - September 22, 2008 - Colorado BioScience Association
AnaSpec Celebrates 15 Year Anniversary
Since its inception in 1993, AnaSpec has provided drug discovery reagents to some of the world’s largest biotech, pharmaceutical, and academic research institutions. - September 21, 2008 - AnaSpec, EGT Group
AnaSpec to Manufacture BD™ Fluorescent Dyes for BD Biosciences
AnaSpec announced today that BD Biosciences, a business segment of BD (Becton Dickinson and Company), has chosen it to manufacture and supply the BD™ H7, Calcein AM and DiIC12(3) Fluorescent Dyes. “BD Biosciences has a tremendous reputation in the industry for innovative products of... - September 19, 2008 - AnaSpec, EGT Group
AnaSpec Introduces High Performance Labeled Streptavidins
AnaSpec has introduced its latest collection of streptavidins labeled with its patented HiLyte Fluor(TM) and HiLytePlus(TM) dyes which promise brighter fluorescence and better photostability compared to FITC and Cyâ dyes. - September 18, 2008 - AnaSpec, EGT Group
Serendipity Discovers the Holy Grail of Regenerative Cardiology
MetaReports.net releases a breakthrough research report that solves regenerative cardiology companies’ unyielding problem of translating positive pre-clinical data into successful human trials. - September 17, 2008 - MRI Limited
RayBiotech and AnaSpec Sign Licensing Agreement for HiLyte™ Dyes
AnaSpec and RayBiotech today announced a licensing agreement that will allow RayBiotech to label antibodies with AnaSpec HiLytePlus™ and HiLyte Fluor™ dyes and integrate into protein and antibody arrays. HiLytePlus™ and HiLyte Fluor™ are AnaSpec's proprietary series of high... - September 17, 2008 - AnaSpec, EGT Group
AnaSpec and Cyclex Sign Licensing Agreement for Deacetylase Activity Assay Kits
AnaSpec and Cyclex Co. Ltd. today announced a licensing agreement that will allow AnaSpec to make, use, and sell deacetylase activity assay kits and the related products as covered by Cyclex’s patent # ‘s EP 1243658, US 7033778, US 7256013. "We are pleased to partner with Cyclex... - September 14, 2008 - AnaSpec, EGT Group
AnaSpec Introduces Kinase Substrates as GO™ Peptides
Protein kinases are a transferase family of self-regulatory enzymes that catalyze the phosphorylation of other proteins by covalently attaching phosphate groups to them, using ATP as a phosphate donor. Reversible protein phosphorylation-dephosphorylation has a principal role in the regulation of... - September 11, 2008 - AnaSpec, EGT Group
Recombinant MOG Proteins - New
Expanding on its world-class collection of MOG peptides and assay kits, AnaSpec is pleased to announce the release of 3 MOG recombinant proteins, for human, mouse and rat. These proteins, with sequences corresponding to human, mouse and rat extracellular domain, together with a 6x His tag were... - September 10, 2008 - AnaSpec, EGT Group
Colorado BioScience Association Seeks Region’s Top Innovators for Venture Showcase Competition at 2008 BioWest Conference & Expo
The organizers of BioWest 2008 are again looking for the best bioscience start-ups in the region as candidates for the $10,000 Dorsey & Whitney Venture Showcase Award. Six companies will be chosen to present at the showcase on Thursday, November 13, 2008, and will be judged by a panel of national venture capitalists. Deadline for entry is Monday, October 1. - September 06, 2008 - Colorado BioScience Association
Accugenix Announces Release of Updated Bacterial Sequence Library: 283 New Entries Continue to Grow Lab’s Impressive DNA Sequence Database
Accugenix, the leader in genetic microbial identification and characterization services, announced today the addition of 283 new species to its extensive Bacterial Library, bringing the total number of unique bacterial DNA sequences on file to over 2400. With this library release, Accugenix continues to provide the pharmaceutical, biotech, medical device, and other manufacturers with rapid, accurate and cost-effective resources to maintain a sterile, safe and compliant environment for consumers. - September 04, 2008 - Accugenix, Inc.
Anavex Completes Successful Preclinical Studies on Lead Alzheimer's Drug Candidate
Anavex completes successful preclinical studies on Anavex 2-73, a novel sigma-1 receptor agonist for the treatment of Alzheimer's disease. - September 04, 2008 - Anavex Life Sciences Corp.
AnaSpec Peptides Used in Latest Alzheimer’s Research Findings by VU University Medical Centre and Lund University
At the 2008 International Conference for Alzheimer’s Disease, the VU University Medical Centre and Lund University presented a joint poster entitled, “Aβ1-42 binding and uptake by primary human astrocytes in vitro: Effects of a1-Antichymotrypsin.” The authors of the study... - August 31, 2008 - AnaSpec, EGT Group
New Anti-GHSR Antibodies from AnaSpec
AnaSpec has announced the release of two antibodies for growth secretagogue receptor (GHSR). One antibody targets the N-terminus and the other an internal sequence. GHSR is a G protein-coupled receptor with seven transmembrane domains and is primarily expressed in hypothalamus and pituitary glands... - August 30, 2008 - AnaSpec, EGT Group
AnaSpec and UW TechTransfer Sign Licensing Agreement for Protein Tyrosine Phosphatases
AnaSpec and UW TechTransfer today announced a licensing agreement that will allow AnaSpec to make, use, and sell Protein Tyrosine Phosphatase Substrates as covered by UW’s patent # 5,739,278 entitled “Compositions for Protein Tyrosine Phosphatases.” "We are pleased to... - August 29, 2008 - AnaSpec, EGT Group
Baxa Corporation Named to Inc. 5000 for Second Consecutive Year as One of the Fastest-Growing Private Companies in the US
Baxa Corporation announces its ranking in the second annual list of top 5,000 fastest-growing private businesses in the US; proof that the economy is not slowing its growth. The company has grown steadily since its founding in 1975 and currently employs more than 450 associates through its Colorado headquarters and UK subsidiary offices. - August 28, 2008 - Baxa Corporation
Cultrex® Mouse Laminin I Now Qualified “PathClear®”
Trevigen adds mouse Laminin I to PathClear® designated products for research involving cancer cell characterization and behavior. - August 22, 2008 - Trevigen, Inc.
Assay Designs Launches First Commercially Available EIA Kit for the Measurement of Circulating Hsp70
For over 15 years, Assay Designs has provided high quality antibodies, proteins, and kits for the precise quantification of key small and large molecule biomarkers in a variety of sample matrices and species. Since their merger with Stressgen® Bioreagents in 2005, the Assay Designs portfolio of products has included the full line of Stressgen brand kits and reagents, enabling researchers to investigate biological pathways involved in the cellular response to stress. - August 15, 2008 - Assay Designs
Biocore and AnaSpec Sign Distributor Agreement
AnaSpec and Biocore Pty Ltd today announced a non-exclusive distributor agreement that will allow Biocore Pty Ltd to distribute AnaSpec’s catalog and custom products throughout Australia. AnaSpec’s Director of Sales & Marketing, Violeta Rajkovska, noted, “AnaSpec is pleased... - August 14, 2008 - AnaSpec, EGT Group
AnaSpec Introduces GO Peptides™ - Research-Ready Peptides on Demand
AnaSpec is pleased to introduce GO Peptides™, the next evolution in peptide tools. - August 13, 2008 - AnaSpec, EGT Group
AnaSpec Introduces New SensoLyte™ 570 Generic MMP Assay Kit with Industry’s Highest Wavelength
Matrix metalloproteinases (MMPs) belong to a family of secreted or membrane-associated proteins capable of digesting extracellular matrix components. The importance of MMPs in tumor development and invasion as well as other diseases is well known. AnaSpec has introduced the SensoLyteTM 570 Generic... - August 09, 2008 - AnaSpec, EGT Group
RemedyMD Promotes Adam Slovik as President and Chief Operating Officer
RemedyMD® Inc., pioneer in the use of predictive informatics to help improve medical outcomes, today announced the promotion of Adam Slovik to President and Chief Operating Officer. “Adam has all the tools and talent to succeed in this role,” said Gary Kennedy, RemedyMD chairman... - August 06, 2008 - RemedyMD Inc.
Anavex Presents Neuroprotective Effects of Anavex 1-41 at the International Conference on Alzheimer's Disease 2008
Anavex Life Sciences presented its new findings of its ANAVEX 1-41 compound targeting Alzheimer's disease at ICAD (July 26 to 31, 2008). - August 02, 2008 - Anavex Life Sciences Corp.
CriticalPoint and Baxa Corp Introduce Crosswalk Tool for Sterile Compounding Regulatory Requirements
CriticalPoint, LLC , in partnership with Baxa Corporation, announces the availability of a free online reference tool for understanding state laws and regulations related to sterile compounding and USP 797 compliance. - July 30, 2008 - Baxa Corporation
Novus Biologicals and AnaSpec Sign Licensing Agreement for HiLyte™ Dyes
AnaSpec and Novus Biologicals today announced a licensing agreement that will allow Novus Biologicals to label Novus antibodies with AnaSpec HiLytePlus™ and HiLyte Fluor™ dyes. HiLytePlus™ and HiLyte Fluor™ are AnaSpec's proprietary series of high performance fluorescent... - July 30, 2008 - AnaSpec, EGT Group
Clinical Trials in Russia. 2nd Quarter 2008
On July 24, 2008 Synergy Research Group (SynRG), a Russia-based CRO, presented the current issue of its Orange Paper, a regular analysis of the clinical trial market in Russia. The report contains hundreds of figures as well as dozens of tables and pictures covering various aspects of the Russian... - July 26, 2008 - Synergy Research Group
AnaSpec Offers Custom Peptide-Aminoluciferin Synthesis
AnaSpec now offers custom synthesis service of peptide-aminoluciferin substrates. - July 23, 2008 - AnaSpec, EGT Group
Baxa Corporation Launches New Electronic Users’ Group Web Site
Baxa Corporation announces the launch of a new electronic users’ group Web site for health-system users of Baxa software and pharmacy automation equipment. This updated version of eBUG, or electronic Baxa Users’ Group provides an Internet community for sharing user experiences and best practices, as well as offering online technical support and tools for improving the user experience with Baxa products. - July 18, 2008 - Baxa Corporation
Colorado BioScience Association Launches New Pilot Externship Program, Connecting Jefferson County High School Science Teacher with Boulder's Array BioPharma
Colorado BioScience Association (CBSA) has announced the debut of a new educational program this summer – an externship for a local high school science teacher at one of the area’s prominent biotechnology companies. Tamra Miaja, a Bear Creek High School biology teacher is the first teacher to take part in CBSA’s pilot externship program and has spent part of her summer at Array BioPharma, headquartered in Boulder. - July 17, 2008 - Colorado BioScience Association
Korea's Largest Biotech Show Kicks Off in Osong
The 3rd BIO KOREA convention will be held from October 8th to 10th at Osong Bio-Technopolis. The event of this year offers a variety of high-level conference, international exhibition and partnership events and provide an opportunity to find business and technology partners. It expects to 350 companies and 25,000 visitors from all over the world. - July 17, 2008 - Bio Korea
Anavex Life Sciences Corp. Will Present New Findings at the International Conference on Alzheimer's Disease 2008 (July 26-31, 2008, Chicago, USA)
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) announces its participation at the International Conference on Alzheimer's Disease 2008 (July 26-31, 2008, Chicago, USA), where it will present results obtained with Anavex 1-41 demonstrating a protective effect against the neurotoxicity... - July 15, 2008 - Anavex Life Sciences Corp.
Trevigen Announces the First Standardized Comet Assay Electrophoresis System (ES) for Direct Detection of DNA Damage
Trevigen, with funding from Phase 1 and Phase II SBIR grants, makes available a novel complete assay system which includes CometSlides™, reagents, control cells and an electrophoresis unit. - July 13, 2008 - Trevigen, Inc.
AnaSpec Introduces New Series of PAR Peptides
AnaSpec has introduced its latest series of PAR peptides. - July 09, 2008 - AnaSpec, EGT Group
New Anti-Keratin Antibodies Introduced by AnaSpec
AnaSpec has introduced two keratin antibodies that recognize both the intact and caspase digested N-terminal of K18 and K19 at Asp237. These antibodies are useful tools for studying keratin dynamics in mice undergoing hepatocyte apoptosis, patients with cirrhosis, and also in apoptotic cells of... - July 04, 2008 - AnaSpec, EGT Group
M-Scan Ltd Successfully Passes GMP Inspections by the FDA and UK MHRA
The world-leading provider of contract analytical services now conducts bio/pharmaceutical analysis to both GMP and GLP (compliant since 1992.) - July 04, 2008 - M-Scan
Colorado Confirmed as Top Bioscience State by National Rankings
It’s been a banner year for Colorado in the highly competitive state rankings arena. Genome Technology’s June publication ranks Colorado as one of the top 20 biotech locations in the world, and the Families USA Global Health Initiative Report ranked Colorado fourth among states that generated the most economic activity per dollar of funding from the NIH. Further, Colorado placed in the top five of all five categories in the Milken Institute’s State Technology and Science Index. - July 02, 2008 - Colorado BioScience Association
A Russian and Pakistani CRO Announce Alliance for Expansion of Global Clinical Trials Services
On June 30, 2008 Synergy Research Group (SynRG), a Russia-based CRO with more than 6-year experience in clinical trials in Russia announced the establishment of a new international CRO alliance with Metrics Research, a Pakistan-based CRO. This is the next step made by SynRG toward the formation of... - July 02, 2008 - Synergy Research Group
New SensoLyte HDAC Assay Kit Introduced by AnaSpec
Histone deacetylase (HDAC) enzymes modulate gene expression through the deacetylation of lysine residues on histone proteins and act as transcriptional repressors of genes. Based on their role in cell cycling, apoptosis and differentiation, HDACs have been chosen as therapeutic targets for the... - June 27, 2008 - AnaSpec, EGT Group
Trevigen Announces a Highly Sensitive, Fluorescent, One Hour PARP Inhibition Assay
Until now, commercially available PARP assay kits required multiple steps and were time consuming. Trevigen overcomes these drawbacks with the release of the HT Fluorescent Homogeneous PARP Inhibition Assay. - June 22, 2008 - Trevigen, Inc.
Xcelience Strengthens Development Services with Addition to Executive Team
The formulation development company’s services are led by an industry pioneer. - June 22, 2008 - Xcelience, LLC
Colorado’s Bioscience Community Celebrates the State’s Largest Medical Device Manufacturer
Gambro BCT, Inc., (to be CaridianBCT, Inc., as of July 14) is the largest medical device manufacturer headquartered in Colorado, with worldwide revenues approaching $500M and 2300 employees. The company had previously been a subsidiary of Gambro AB, a publicly traded, multinational healthcare company based in Sweden. The name CaridianBCT combines two words “care” and “meridian” to highlight the manufacturer's commitment to care and global reach. - June 20, 2008 - Colorado BioScience Association
Anavex Further Strengthens Board of Directors
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) today announced the appointment of David L. Tousley, CPA, MBA, to its Board of Directors. Mr. Tousley is an accomplished professional with many years of experience as a senior financial and operations executive in start-up and... - June 20, 2008 - Anavex Life Sciences Corp.